Fibralign Corporation voted 2014 MedTech Innovator

MedTech Innovator 2014 was held June 12, 2014 during the 22nd Annual Medical Device Conference, hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR)



267 companies submitted their plans. A panel of investor judges reviewed the entries to select the MedTech Innovator Top 10 Semi-Finalists. The investor judges included Christopher P. Martin, President, RCT Ventures; Ned Scheetz, Founder & Managing Director, Aphelion Capital; James Dreher, Managing Partner, Option 3; and Brad H. Vale, Ph.D., D.V.M., Head, Johnson & Johnson Development Corporation (JJDC). The competition was produced by RCT Ventures, and the event's Master of Ceremonies was Paul Grand, Managing Director, RCT Ventures.

The final phase of the competition took place live on stage during the 22nd Annual Medical Device Conference, hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR) in front of an audience of more than 600 industry professionals in San Francisco. The 10 Semi-finalists competed to be among 4 Finalists who gave 5-minute presentations followed by 5 minutes of Q & A from the judges. The audience then voted in real-time for the winner using their mobile devices, which was Fibralign Corporation. The second place winner was Francis Lamont Innovations (FLI).

Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The Company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.

"It was a real honor to be chosen from among our peers as this year's MedTech Innovator winner," said Greg King, COO of Fibralign. "This award provides Fibralign needed visibility to better address this significant opportunity. The competition was a fantastic experience, because it put a much-deserved spotlight on great startups selected from around the world. These companies provide a diverse range of breakthrough products that offer creative ways to improve patient care."

RCT Ventures produced the competition and contributed a $100,000 cash prize for the winner. "I was thrilled to see an innovative company like Fibralign win the 2014 MedTech Innovator competition, which seeks to identify outstanding early-stage MedTech opportunities and help them succeed," said Grand. "Fibralign was voted the winner by an audience made up of over 600 venture capitalists, corporates, and industry professionals. That kind of exposure and engagement would typically take months or years and has the potential to result in a financing or key industry partnership."

In addition to RCT's $100,000 contribution, several of the Johnson & Johnson family of companies contributed $25,000 to Fibralign's prize, and the second place winner, FLI, also received $25,000. Additionally, Janssen Labs, a life science incubator, is providing entry to the Janssen Labs community for Fibralign for one year, valued at $25,000. "Across the Johnson & Johnson Family of Companies, we take pride in supporting innovators and entrepreneurs in the life science community," notes Dr. Brad Vale, Head of Johnson & Johnson Development Corporation. "We work with emerging companies to help advance their science and technology into products that change people's lives."

In addition to the cash prizes, Fibralign received several prizes designed to give the company broad exposure to investors and industry. The company will be profiled in an upcoming issue of the MedTech Innovation Report. Fibralign will also get a presentation slot and complimentary full access registration to this October's AdvaMed 2014 conference in Chicago, which is expected to attract more than 2,500 investors and MedTech industry professionals.






Meet the 2014 MedTech Innovator Top 10


The Team

  • Paul Grand
  • Chris Martin
  • Ned Scheetz
  • Brad Vale
  • James Dreher